NASDAQ · Biotechnology

Allogene Therapeutics Inc (ALLO)

$2.09 -0.48%

Add alert

55 In band Daily RSI (14) · 21 Aug 2026

Moving averages

SMA 200$1.89+10.58%

Company profile

Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.

SectorHealthcare

IndustryBiotechnology

Market cap$683.41M

P/E ratioNone

EPS$-0.66

Beta0.466

Dividend yield0.00%

52-week high$4.46

52-week low$1.03

Similar stocks in Biotechnology

BNTX BioNTech SE RSI 79 VRTX Vertex Pharmaceuticals Inc RSI 67 CRSP CRISPR Therapeutics AG RSI 67 IOVA Iovance Biotherapeutics Inc RSI 72 MRNA Moderna Inc RSI 72 VKTX Viking Therapeutics Inc RSI 48 SRPT Sarepta Therapeutics Inc RSI 59 EDIT Editas Medicine Inc RSI 57 NVAX Novavax Inc RSI 63 DNA Ginkgo Bioworks Holdings Inc - Class A RSI 46

Free forever

RSI alerts for ALLO

Get an email the moment Allogene Therapeutics Inc crosses into oversold or overbought territory. Nothing else, ever.

Add alert

Data last updated 14 August 2026 at 9:11 AM EDT